Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence, pentostatin | 1.00 |
| trials ClinicalTrials.gov | ClinicalTrials.gov did not answer (ClinicalTrials.gov: HTTP 400) | 0.00 |
| literature PubMed | 22 Parkinson's papers of 14,823 | 0.59 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7615
Sealed predictions
- ADA in dopamine neurons, braak+0.10 (p 0.807) → -0.05 (p 0.906)receipt 7623
Swarm cases
receipt 7623: ADA in dopamine neurons, braak
- power
- full sample -0.07 (p 0.794, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.840, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.09 (p 0.728, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.05, sign flips 3; without severely affected donors -0.07 (p 0.794, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.63 (p 0.0055, n 18) vs -0.07 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADA in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ADA · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.07 p 0.790 (needs p < 2.8e-4)
Receipts
loading the receipts